ALLMedicine™ Cold Agglutinin Disease Center

May 17th, 2022 - The author report an interesting case of relapsed diffuse large B-cell lymphoma (DLBCL) with bone marrow (BM) and peripheral blood (PB) involvement after prior cold agglutinin disease (CAD). A minority of patients with DLBCL present with CAD, and ...

May 9th, 2022 - The period between screening/baseline visit (upon the participant's completion* of the CARDINAL and CADENZA studies) and end of treatment with sutimlimab in this study is determined by sutimlimab or other appropriate CAD therapy becoming commercia...

Apr 30th, 2022 - Impaired immune response with uncontrolled inflammation and various immunological disorders have been reported during SARS-CoV-2 infection. Here, we report a case of cold agglutinin disease occurring during a severe coronavirus disease 2019 (COVID...

Apr 13th, 2022 - Sutimlimab (sutimlimab-jome; ENJAYMO™) is a humanized monoclonal antibody developed by Sanofi for the treatment of cold agglutinin disease (CAD). Sutimlimab is an immunoglobulin G, subclass 4 (IgG4) monoclonal antibody that inhibits the classical ...

Apr 13th, 2022 - Necrosis secondary to cold agglutinin disease.|2022|Nakagawa H,Kato C,Miyata Y,|complications,diagnosis,

May 9th, 2022 - The period between screening/baseline visit (upon the participant's completion* of the CARDINAL and CADENZA studies) and end of treatment with sutimlimab in this study is determined by sutimlimab or other appropriate CAD therapy becoming commercia...

Mar 22nd, 2022 - The purpose of the study is to determine the efficacy of pegcetacoplan administration compared to placebo in increasing hemoglobin (Hgb) level from baseline and avoiding transfusion in participants with primary cold agglutinin disease (CAD).

Jan 9th, 2017 - Background Chronic cold agglutinin disease (CAD) is mediated by monoclonal cold-reactive autoantibodies that bind to erythrocyte surface antigens, causing hemagglutination and complement-mediated hemolysis. Anemia is severe in one-third of patient...

Jun 22nd, 2010 - 1. Background Chronic cold agglutinin disease (CAD) is mediated by monoclonal cold-reactive autoantibodies that bind to erythrocyte surface antigens, causing haemagglutination and complement-mediated haemolysis. Anaemia is severe (Hb 8.0 g/dL or l...

Feb 23rd, 2022 - Craig Kessler, MD: Sutimlimab is a humanized monoclonal antibody that selectively inhibits activation of the complement pathway by binding to complement 1S. This drug, which is not approved, will be marketed by Sanofi. It was originally developed ...

Feb 10th, 2022 - A 30-year-old investigational drug could get another look as a potential cancer therapy as a result of the growing emphasis on precision medicine. (VCU Health, Molecular Cancer Therapeutics) The Centers for Medicare & Medicaid Services expanded el...

Feb 7th, 2022 - A new drug has become the first and only treatment for people with cold agglutinin disease (CAD) that is approved by the US Food and Drug Administration (FDA). CAD is a rare autoimmune hemolytic anemia, affecting about 5000 people in the United St...

Nov 18th, 2021 - Cold agglutinin disease (CAD) is a rare, complement-dependent, classical pathway–mediated immune hemolytic disease, accounting for up to 25% of autoimmune hemolytic anemia. Whereas the incidence of CAD is rare, the disease burden is frequently hig...

May 14th, 2020 - FILE PHOTO: The logo of Sanofi is seen at the company's headquarters in Paris, France, April 24, 2020. REUTERS/Charles Platiau PARIS (Reuters) - French healthcare company Sanofi said on Thursday that the U.S. Food & Drug Administration (FDA) regul...